Aim: The aim of this study was to analyse allelic loss of the phosphatase and tensin homologue deleted on chromosome 10 (PTEN) gene and its protein immuno-expression in dysplastic oral lesions and oral squamous cell carcinomas (OSCCs). Methods and results: Samples were collected from 153 patients [20 ranulas used as a control (C); 30 leucoplakias with mild dysplasia (MD); 30 leucoplakias with moderate to severe dysplasia (MSD); 73 oral squamous cell carcinoma (OSCC)]. PTEN protein expression was investigated using immunohistochemistry, and PTEN allelic loss was analysed by fluorescence in-situ hybridisation (FISH). Differences among groups were evaluated using the v 2 test.
Introduction
Oral squamous cell carcinoma (OSCC) is one of the most common types of cancer in the world, 1 accounting for more than 95% of all malignant neoplasms in the oral cavity. It is a significant problem in many parts of the world, particularly in underdeveloped countries, owing to its high incidence and unsatisfactory 5-year survival rate and because treatment can result in severe functional and cosmetic defects. 2 Oral carcinogenesis is a multistep process that involves the activation of proto-oncogenes and inactivation of tumour suppressor genes. However, the underlying molecular mechanisms remain to be understood fully. A proportion of OSCCs develop from oral potentially malignant lesions, such as oral leucoplakia, oral submucous fibrosis and oral erythroplakia.
The presence and degree of epithelial dysplasia are used to assess the risk of leucoplakia progression to malignancy; however, histological grading has limited value in predicting the individual risk of each case. Furthermore, the criteria reproducibility of microscopic grading of dysplastic lesions is very low, and poses significant difficulties among pathologists. [3] [4] [5] Therefore, the understanding of the molecular mechanisms that govern the evolution of oral potentially malignant lesions into OSCC is highly relevant for clinical practice, leading potentially to the identification of genes and proteins suitable for therapeutic targeting and predictors of prognostic determination. [5] [6] [7] Akt/protein kinase B is a major downstream target of growth factor receptor tyrosine kinase that signals via phosphatidylinositol-3 kinase (PI3K), and is activated frequently in different human malignancies. 6, [8] [9] [10] Phospho-Akt (p-Akt) controls a variety of critical cellular pathways during the carcinogenic process, including those leading to apoptosis inhibition and increased cell proliferation, as well as enhanced tumour cell invasion, angiogenesis and cell metabolism, through glucose metabolism. 6, 11 Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) is a tumour suppressor gene, and its major substrate is phosphatidylinositol (3,4,5)-triphosphate (PIP-3), which dephosphorylates PIP3 to regenerate PIP2 and which antagonises PI3K function. Consequently, PTEN down-regulates Akt activity by dephosphorylating and regulating PI3K signalling negatively. 12 Conversely, loss of PTEN expression results in increased Akt activity and continued cell survival and proliferation.
Recent studies have proposed that activation of Akt has been shown to be associated with advanced stages and poor prognosis in OSCC; 7, [13] [14] [15] furthermore, studies using OSCC cell lines have shown that induced PTEN overexpression down-regulated Akt phosphorylation significantly and induced apoptosis. 16 Regarding oral potentially malignant lesions, several studies have shown that p-Akt may play an important role in the conversion of these lesions to its malignant counterpart. 6, 7, 15, 17 The expression of PTEN in potentially malignant oral lesions remains to be investigated, and its importance to the oral carcinogenesis process deserves to be understood more clearly. Therefore, the aim of this study was to determine the expression and the allelic loss of PTEN in oral leucoplakia with different degrees of epithelial dysplasia and in OSCC.
Materials and methods

T I S S U E S A M P L E S
Samples were collected from the Service of Oral Pathology of the João de Barros Barreto University Hospital (Bel em, Brazil). The local ethics committee approved this study (process no. 1 426 757).
The specimens were obtained from 153 patients [20 samples of morphologically normal epithelium obtained from ranulas with inflammatory infiltrated located distant from the overlying epithelium to be used as a control group (group C); 30 oral leucoplakias with mild dysplasia (MD); 30 leucoplakias with moderate to severe dysplasia (MSD); and 73 OSCC]. Histological sections (5 lm) of all samples were stained routinely with haematoxylin and eosin (H&E) and analysed under light microscopy. Two independent oral pathologists without prior knowledge of the clinical data assessed the stained sections to classify the histological grades of oral dysplasia according to a previously proposed binary system criteria of classification. 3 In cases of disagreement, pathologists discussed the findings and achieved a final agreement.
I M M U N O H I S T O C H E M I S T R Y
Immunohistochemical reactions were performed in 3 lm sections that were dewaxed with xylene and rehydrated in ethanol series. Antigen retrieval was performed by immersing the slides in an ethylenediamine tetraacetic acid (EDTA) solution (pH 8.0) for 15 min in a microwave oven. Peroxidase activity was blocked with a 6% hydrogen peroxide and methanol (1:1) solution in two baths of 15 min each at room temperature. After washing in Tris buffer (pH 7.4), the slides were incubated with primary antibody (polyclonal anti-human PTEN; Invitrogen, Carlsbad, CA, USA) in a dilution of 1:100 overnight for 18 h at 4°C. The slides were subsequently exposed to the avidin-biotin complex [LSABKit + horseradish peroxidase (HRP); Dako Cytomation, Glostrp, Denmark] and to the 3,3 0 -diaminobenzidine chromogen (DAB+; Dako Cytomation). The sections were counterstained with Mayer's haematoxylin, dehydrated in ethanol, cleared in xylene and mounted. Prostate cancer tissue was used as a positive control; the negative control was obtained by omitting the primary specific antibody during the reaction. The results were considered positive when brown-coloured nuclear and cytoplasmic stainings were observed, characterising the presence of DAB in the immunohistochemical reaction.
The scoring system used has been described previously in the literature. 18 Briefly, the analysis was based on both the intensity and distribution of staining. The distribution of stained cells was organised as follows: 0 (0% of cells stained), 1 (1-50% of cells stained) and 2 (51-100% of cells stained). The intensity of staining was rated as follows: 0 (no staining), 1 (mild staining), 2 (moderate staining) and 3 (strong staining). The final record for each case was defined by the sum of the values obtained as follows: FR0, FR2, FR3, FR4 and FR5. Finally, FR0 and FR2 were considered negative staining, while FR3, FR4 and FR5 were considered positive staining.
F L U O R E S C E N C E I N -S I T U H Y B R I D I S A T I O N
For FISH analysis, 5 lm histological sections of 10% formalin-fixed tissues were dewaxed in xylene and rehydrated in ethanol series. The denaturation process was carried out on a hot plate at 95°C for 10 min. Five ll of PTEN probe were applied on the samples according, to the manufacturer's instructions (Cat. no. 07J74001, Vysis LSI PTEN SpectrumOrange/CEP 10 SpectrumGreen Probes; Abbott Molecular Inc., Des Plaines, IL, USA). The samples were incubated in a humid chamber protected from light at 37°C for approximately 16 h. Sections were stained with 4 0 ,6-diamidino-2-phenylindole, dihydrochloride (DAPI), and the slides were incubated in a humid chamber protected from light for 10 min at 8°C.
Analysis was performed using an Olympus BX 41 fluorescence microscope using the Case Data Manager 5.0 program, where 100 cells/case were counted randomly regarding the probe signals in each allele of the gene investigated. Hemizygous (single-copy) PTEN deletion was assigned when >50% of nuclei exhibited clonal loss of PTEN and adjacent probes. Homozygous PTEN deletion was defined by a simultaneous lack of both PTEN locus signals in 30% of scored nuclei. 19 
S T A T I S T I C A L A N A L Y S I S
To determine any significant difference regarding the allelic loss of PTEN and its immuno-expression among the groups investigated, a v 2 test was applied. GraphPad Prism version 5.0 (GraphPad Software, San Diego, CA, USA) was used for statistical analysis, and statistical significance was set at P < 0.05 with 95% confidence intervals.
Results
The clinicopathological characteristics of 60 patients with leucoplakia and 73 patients with OSCC are summarised in Tables 1 and 2 . 1.3) . The majority of the cases affected the tongue (53.33%), followed by the floor of the mouth (16.67%).
I M M U N O H I S T O C H E M I C A L S T A I N I N G
PTEN immunoreaction showed, predominantly, a cytoplasmatic staining. However, nuclear staining was sometimes observed. In normal oral mucosa and dysplastic tissues, the immunoreaction was found predominantly in the parabasal and basal layers, whereas OSCC showed a diffuse distribution in neoplastic islands (Figure 1) .
In the C group, 35% (seven cases) were positive for PTEN immuno-expression, whereas 65% (13 cases) were negative. In the oral leucoplakia group, MD showed that 43.33% (13 cases) were positive and 56.67% (17 cases) were negative, whereas MSD showed positivity in 80% of the cases (24 cases) and 20% (six cases) demonstrated negativity. Regarding OSCC samples, 63.01% (46 cases) were positive and 36.99% (27 cases) were negative.
PTEN expression was higher in MSD (P = 0.002) and OSCC (P = 0.0259) compared with the C group. Additionally, a higher expression was observed in MSD (P = 0.0035) and OSCC (P = 0.049) than MD (Table 3) .
F L U O R E S C E N C E I N -S I T U H Y B R I D I S A T I O N A N A L Y S I S
All samples of normal epithelium did not demonstrate allelic loss. In MD, only 3.33% (one of 30) showed homozygous deletion; in MSD, 3.33% (one of 30) showed a PTEN hemizygous (single copy) deletion, whereas 10% (three of 30) showed homozygous deletion. In OSCC samples, single-copy loss was observed in 13.70% (10 of 73) of the cases, and bi-allelic loss occurred in 20.55% (15 of 73) (Figure 2 ). Statistically, a higher hemizygous loss was observed in OSCC than C (P = 0.0467) and OSCC than MD (P = 0.0175), as well as a higher homozygous deletion in OSCC than C (P = 0.0159) and OSCC than MD (P = 0.0145) ( Tables 4 and 5 ).
Discussion
Despite advances in therapeutic approaches, the morbidity and mortality associated with OSCC have not improved significantly in the last 30 years, with the 5-year overall survival rate varying between 30% and 50%. 13 OSCC may be preceded by a potentially malignant lesion, and the presence of epithelial dysplasia seems to be the most important prognostic indicator of its potential for malignant transformation; 20 however, the incidence of malignant change varies in different studies, possibly as a result of differences in ethnic and environmental factors. 6 Moreover, the low reproducibility of current histological criteria for grading epithelial dysplasia is largely recognised and remains to be improved. These facts highlight the necessity of identifying molecular markers that could predict oral leucoplakia aggressiveness and clinical course more clearly. For this reason, it is crucial to understand the deregulated molecular pathways that govern the progression of oral carcinogenesis. 6, 21, 22 PTEN is a tumour suppressor that opposes PI3K function by dephosphorylating PIP3 to regenerate PIP2. It is believed that down-regulation of PTEN leads to an accumulation of PIP3, leading to increased activation of PI3K and pAkt. pAkt participates in the regulation of the cell cycle, proliferation, apoptosis, cell adhesion, migration, invasion and metastasis during cancer progression by regulating various downstream substrates.
Therefore, in this study, we investigated the allelic loss of PTEN and its immuno-expression in dysplastic oral lesions and in OSCC. We employed the binary system to graduate dysplasia because this system has been proved to be a reliable tool, reducing variability and enhancing the reproducibility of epithelial dysplasia. 3, 23 Our results revealed that PTEN expression was higher in MSD (P = 0.002) and in OSCC (P = 0.0259) when both were compared with the C group; moreover, a higher expression was observed in MSD (P = 0.0035) and OSCC (P = 0.049) than MD. In addition, a higher hemizygous loss was observed in OSCC than C (P = 0.0467) and OSCC than MD (P = 0.0175), as well as a higher homozygous deletion in OSCC when compared with C (P = 0.0159) and in OSCC when compared with MD (P = 0.0145). To the best of our knowledge, this is the first study analysing the expression and PTEN allelic loss in oral leucoplakias and in OSCC together. The molecular mechanism underlying malignant transformation of leucoplakias has not yet been elucidated. It is now accepted widely that there are divergent molecules and pathways that affect the process of transformation from leucoplakia to oral squamous cell carcinoma sequentially. 24, 25 Recently, the tumour microenvironment was shown to carry out an important role in oral leucoplakia and oral cancer progression. 26, 27 In addition, several factors including age, sex, smoking and oral subsite, as well as dysplasia grade, have been suggested as predictors of the risk of malignant transformation of oral leucoplakia. [26] [27] [28] These lines of evidence suggest that carcinogenic transformation of a leucoplakia is multifactorial and is patient-specific. 29 Therefore, it is possible that inter-individual and interpopulation differences in risk could be explained partially by different distributions of genetic variants that may cause variation in the ability to metabolise carcinogens and/or effective repair of the damage caused by them. 30 The above observations contribute to understanding of 20% of negative expression of PTEN in MSD group and 37% of negative expression in OSSC group. We must also keep in mind that some oral cancers can develop from lesions that lack dysplastic changes. 31, 32 On this basis we can explain, in some measure, the proportion of cases in the C group with expression-positive PTEN.
Recently, Chaves et al. studied p-Akt function in oral epithelial dysplasia and in OSCC, observing that p-Akt immunostaining was significantly higher in the malignancy group than in dysplasias and controls. 15 Other studies investigated p-Akt in the process of malignant transformation of oral epithelium, suggesting that activation of the PI3K-AKT signal pathway is involved in the malignant phenotype acquisition process from its early stages. 6, 7, 33 In addition, Akt expression was shown to be a prognostic determinant for patients affected by OSCC. 13, 34 In this regard, in our work the increase in PTEN expression observed in the evolution of dysplastic lesions can be understood as an attempt to control the increased expression of Akt described in several studies of oral dysplastic lesions. 6, 7, 15, 33 In addition, a decrease in PTEN expression was observed in OSCC. Reduced PTEN protein expression in OSCC has also been observed in previous studies, 21, 35, 36 suggesting a PTEN functional inactivation in this malignancy.
Here we also investigated the loss of PTEN copy number in oral dysplastic lesions. Our results showed that the loss of PTEN copy number in oral leucoplakias can represent an important mechanism for the development of oral potentially malignant lesions into progression to oral cancer when the loss of PTEN copy number occurred in 34.25% of our sample (10 hemizygous deletion and 15 homozygous deletion). As PTEN is a tumour suppressor gene, for its complete inactivation there is a need for both copies to be deleted. In the cases of OSCC in which there was hemizygous deletion, evaluation of the mutation or hypermethylation of the PTEN promoter region in the remaining alleles may elucidate whether the loss of PTEN expression in OSCC samples would be occurring through genetic or epigenetic events. Some authors have already addressed this issue, demonstrating that mutation in PTEN is a rare event in HNSCC, [36] [37] [38] [39] [40] [41] whereas others have shown that hypermethylation of the PTEN promoter region is frequent in this tumour, 36, 42 which is an important mechanism of epigenetic silencing that may contribute to cancer.
Some papers highlight that homozygous deletion is unlikely to play a key role in the PTEN inactivation process in OSCC. 43, 44 However, in this study bi-allelic loss occurred in 20.55% of the OSCC group. This homozygous loss of PTEN alleles was statistically higher in OSCC samples when compared with lesions that presented in MD and the C group. An important increase in loss of both alleles was observed in OSSC when compared with MSD, although there was no statistically significant difference.
In conclusion, taking into consideration the fact that longitudinal studies are more indicated to attribute predictive value for malignant transformation, this cross-sectional study permits only speculation, to some extent, that PTEN bi-allelic loss can be an important mechanism in the late stage of development of oral potentially malignant lesions into oral cancer. Moreover, we observed an increase in the expression of PTEN in the dysplastic lesions, suggesting an attempt of PTEN to control the increased expression of Akt. After acquisition of the malignant phenotype, a decrease in PTEN expression was observed, which may be explained by the increased deletion in this group.
